There is a distinct increase in the prevalence of depression with the onset of puberty. The role of peripubertal testosterone levels in boys in this context is insufficiently understood and may be modulated by a functional polymorphism of the androgen receptor gene (AR), a variable number of CAG repeats. Moreover, there is preliminary evidence that the relationship between testosterone, CAG repeat length, and the severity of depressive symptoms may differ between subclinical and overt depression, but this has neither been studied in a clinical sample of adolescents with depression nor compared between subclinical and overt depression in an adequately powered study. To investigate the relationship between free testosterone, CAG repeat length of the AR, depression status (subclinical vs. overt), and the severity of depressive symptoms, 118 boys treated as in- or daycare patients at a single psychiatric hospital were studied. Of these, 73 boys had at least mild depressive symptoms accordi
PHILADELPHIA – Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research , a journal of the American Association for Cancer Research.
Kintor s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
January 19, 2021 08:30 ET | Source: Veru Inc. Veru Inc. Miami, Florida, UNITED STATES International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR Activating Agent as a Potential Therapy in Patients with ER+ Metastatic Breast Cancer that have Become Resistant to Current Standard of Care Treatments Veru Also Announces that the Enobosarm Phase 3 Registration ARTEST Study is on Track to Commence Next Quarter in Patients with Metastatic ER+ Breast Cancer that is Resistant to Estrogen Receptor Targeted Endocrine Therapy and CDK4/6 Inhibit